LPTX Leap Therapeutics Inc.

1.47
-0.01  -1%
Previous Close 1.48
Open 1.51
Price To Book 3.2
Market Cap 35,337,035
Shares 24,038,799
Volume 112,183
Short Ratio
Av. Daily Volume 373,688

NewsSee all news

  1. Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination at the 2019 International Gynecologic Cancer Society Annual Global Meeting

    CAMBRIDGE, Mass., Sept. 17, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today announced an oral and poster presentation of updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its

  2. Leap Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Sept. 4, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D.,

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due 4Q 2019.
TRX518 in combination with gemcitabine chemotherapy or KEYTRUDA or Opdivo
Advanced solid tumors
Phase 1/2 data August 6, 2019 noted 50% ORR.
DKN-01 + KEYTRUDA
Esophagogastric adenocarcinoma
Phase 1/2 data released December 14, 2018 noted 21.3% PR rate.
DKN-01
Biliary tract cancer (BTC)
Phase 2 updated data due September 20, 2019 at IGCS.
DKN-01 and Paclitaxel
Endometrial Cancer
Phase 1/2 trial to be initiated.
TRX518 and avelumab
Solid tumors

Latest News

  1. Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination at the 2019 International Gynecologic Cancer Society Annual Global Meeting

    CAMBRIDGE, Mass., Sept. 17, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today announced an oral and poster presentation of updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its

  2. Leap Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Sept. 4, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D.,